“`html
High-Grade Endometrial Cancer: Advancements and Challenges
Recent research has made significant progress in women’s health, but the diagnosis and treatment of high-grade endometrial cancer (EnCa) have been overlooked. Integrating molecular classification with histology and profiling for mismatch repair deficiency and HER2 overexpression can provide valuable insights for treating drug-resistant recurrent EnCa. Early phase trials have shown that combination therapy with agents having different mechanisms of action is a promising approach for treatment, regardless of EnCa subtype.
Challenges and Opportunities
- High-grade EnCa research is not as extensive as other gynecologic and breast cancers.
- There is a need to integrate molecular profiling and biomarker development with new treatment options to improve efficacy and safety for those with high-grade recurrent EnCa.
“`
